Literature DB >> 7206101

Simultaneous occurrence of transitional, squamous and adenocarcinoma of the bladder after 15 years of cyclophosphamide ingestion.

G W Chodak, F W Straus, H W Schoenberg.   

Abstract

We report on a patient who had a urothelial tumor with tri-differentiation into transitional squamous and adenocarcinoma after ingestion of 285 gm. cyclophosphamide during a 15-year-period. The possibility is again raised that the use of high doses of this drug over long periods may be associated with an increased incidence of carcinoma of the bladder. Frequent cystoscopic examinations may be warranted in patients who have received large cumulative amounts of the drug

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7206101     DOI: 10.1016/s0022-5347(17)55061-2

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  2 in total

1.  Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma.

Authors:  Bjoern G Volkmer; Evelyn M Seidl-Schlick; Dietmar Bach; Imre Romics; Klaus Kleinschmidt
Journal:  Clin Rheumatol       Date:  2004-12-01       Impact factor: 2.980

Review 2.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.